183 related articles for article (PubMed ID: 19402868)
1. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma.
Cawood TJ; Bridgman P; Hunter L; Cole D
Intern Med J; 2009 Apr; 39(4):266-7. PubMed ID: 19402868
[No Abstract] [Full Text] [Related]
2. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
3. The cabergoline-resistant prolactinoma patient: new challenges.
Molitch ME
J Clin Endocrinol Metab; 2008 Dec; 93(12):4643-5. PubMed ID: 19056842
[No Abstract] [Full Text] [Related]
4. A case of iatrogenic severe mitral regurgitation.
D'Aloia A; Piovanelli B; Rovetta R; Bonadei I; Vizzardi E; Curnis A; Metra M
Monaldi Arch Chest Dis; 2013 Sep; 80(3):133-6. PubMed ID: 24818320
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline use for pituitary tumors and valvular disorders.
Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
[TBL] [Abstract][Full Text] [Related]
6. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
7. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
[TBL] [Abstract][Full Text] [Related]
8. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
[TBL] [Abstract][Full Text] [Related]
9. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
Elenkova A; Shabani R; Kalinov K; Zacharieva S
Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
[TBL] [Abstract][Full Text] [Related]
10. Pneumocephalus during cabergoline treatment of an invasive macroprolactinoma.
Jouret F; Col V
Acta Clin Belg; 2009; 64(5):457. PubMed ID: 19999399
[No Abstract] [Full Text] [Related]
11. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline treatment of pregnant women with macroprolactinomas.
Laloi-Michelin M; Ciraru-Vigneron N; Meas T
Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
[No Abstract] [Full Text] [Related]
14. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
Kars M; Pereira AM; Bax JJ; Romijn JA
Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
[TBL] [Abstract][Full Text] [Related]
15. Pituitary apoplexy associated with cabergoline therapy.
Chng E; Dalan R
J Clin Neurosci; 2013 Dec; 20(12):1637-43. PubMed ID: 24113159
[TBL] [Abstract][Full Text] [Related]
16. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
17. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
Caputo C; Prior D; Inder WJ
Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particles in the mitral and tricuspid valves explanted from a patient treated with Fenfluramine-Phentermine.
Garon CF; Oury JH; Duran CM
J Heart Valve Dis; 1999 Mar; 8(2):232. PubMed ID: 10224584
[No Abstract] [Full Text] [Related]
19. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
Gu H; Luck S; Carroll PV; Powrie J; Chambers J
Clin Endocrinol (Oxf); 2011 May; 74(5):608-10. PubMed ID: 21198745
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
Mohan N; Chia YY; Goh GH; Ting E; Teo K; Yeo TT
BMJ Case Rep; 2017 Nov; 2017():. PubMed ID: 29102970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
